BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 38129659)

  • 1. TREX1 is required for microglial cholesterol homeostasis and oligodendrocyte terminal differentiation in human neural assembloids.
    Goldberg G; Coelho L; Mo G; Adang LA; Patne M; Chen Z; Garcia-Bassets I; Mesci P; Muotri AR
    Mol Psychiatry; 2024 Mar; 29(3):566-579. PubMed ID: 38129659
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modeling of TREX1-Dependent Autoimmune Disease using Human Stem Cells Highlights L1 Accumulation as a Source of Neuroinflammation.
    Thomas CA; Tejwani L; Trujillo CA; Negraes PD; Herai RH; Mesci P; Macia A; Crow YJ; Muotri AR
    Cell Stem Cell; 2017 Sep; 21(3):319-331.e8. PubMed ID: 28803918
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cutting Edge: cGAS Is Required for Lethal Autoimmune Disease in the Trex1-Deficient Mouse Model of Aicardi-Goutières Syndrome.
    Gray EE; Treuting PM; Woodward JJ; Stetson DB
    J Immunol; 2015 Sep; 195(5):1939-43. PubMed ID: 26223655
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The TREX1 exonuclease R114H mutation in Aicardi-Goutières syndrome and lupus reveals dimeric structure requirements for DNA degradation activity.
    Orebaugh CD; Fye JM; Harvey S; Hollis T; Perrino FW
    J Biol Chem; 2011 Nov; 286(46):40246-54. PubMed ID: 21937424
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TREX1 is expressed by microglia in normal human brain and increases in regions affected by ischemia.
    Kothari PH; Kolar GR; Jen JC; Hajj-Ali R; Bertram P; Schmidt RE; Atkinson JP
    Brain Pathol; 2018 Nov; 28(6):806-821. PubMed ID: 30062819
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A nationwide survey of Aicardi-Goutières syndrome patients identifies a strong association between dominant TREX1 mutations and chilblain lesions: Japanese cohort study.
    Abe J; Nakamura K; Nishikomori R; Kato M; Mitsuiki N; Izawa K; Awaya T; Kawai T; Yasumi T; Toyoshima I; Hasegawa K; Ohshima Y; Hiragi T; Sasahara Y; Suzuki Y; Kikuchi M; Osaka H; Ohya T; Ninomiya S; Fujikawa S; Akasaka M; Iwata N; Kawakita A; Funatsuka M; Shintaku H; Ohara O; Ichinose H; Heike T
    Rheumatology (Oxford); 2014 Mar; 53(3):448-58. PubMed ID: 24300241
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aicardi-Goutières syndrome protein TREX1 suppresses L1 and maintains genome integrity through exonuclease-independent ORF1p depletion.
    Li P; Du J; Goodier JL; Hou J; Kang J; Kazazian HH; Zhao K; Yu XF
    Nucleic Acids Res; 2017 May; 45(8):4619-4631. PubMed ID: 28334850
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The TREX1 C-terminal region controls cellular localization through ubiquitination.
    Orebaugh CD; Fye JM; Harvey S; Hollis T; Wilkinson JC; Perrino FW
    J Biol Chem; 2013 Oct; 288(40):28881-92. PubMed ID: 23979357
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dominant mutation of the TREX1 exonuclease gene in lupus and Aicardi-Goutieres syndrome.
    Fye JM; Orebaugh CD; Coffin SR; Hollis T; Perrino FW
    J Biol Chem; 2011 Sep; 286(37):32373-82. PubMed ID: 21808053
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Arg-62 residues of the TREX1 exonuclease act across the dimer interface contributing to catalysis in the opposing protomers.
    Fye JM; Coffin SR; Orebaugh CD; Hollis T; Perrino FW
    J Biol Chem; 2014 Apr; 289(16):11556-11565. PubMed ID: 24616097
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Generation of three iPSC lines from fibroblasts of a patient with Aicardi Goutières Syndrome mutated in TREX1.
    Ferraro RM; Lanzi G; Masneri S; Barisani C; Piovani G; Savio G; Cattalini M; Galli J; Cereda C; Muzi-Falconi M; Orcesi S; Fazzi E; Giliani S
    Stem Cell Res; 2019 Dec; 41():101580. PubMed ID: 31644995
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of interferon-related biomarkers in Aicardi-Goutières syndrome associated with mutations in TREX1, RNASEH2A, RNASEH2B, RNASEH2C, SAMHD1, and ADAR: a case-control study.
    Rice GI; Forte GM; Szynkiewicz M; Chase DS; Aeby A; Abdel-Hamid MS; Ackroyd S; Allcock R; Bailey KM; Balottin U; Barnerias C; Bernard G; Bodemer C; Botella MP; Cereda C; Chandler KE; Dabydeen L; Dale RC; De Laet C; De Goede CG; Del Toro M; Effat L; Enamorado NN; Fazzi E; Gener B; Haldre M; Lin JP; Livingston JH; Lourenco CM; Marques W; Oades P; Peterson P; Rasmussen M; Roubertie A; Schmidt JL; Shalev SA; Simon R; Spiegel R; Swoboda KJ; Temtamy SA; Vassallo G; Vilain CN; Vogt J; Wermenbol V; Whitehouse WP; Soler D; Olivieri I; Orcesi S; Aglan MS; Zaki MS; Abdel-Salam GM; Vanderver A; Kisand K; Rozenberg F; Lebon P; Crow YJ
    Lancet Neurol; 2013 Dec; 12(12):1159-69. PubMed ID: 24183309
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dysregulation of the immune system in Aicardi-Goutières syndrome: another example in a TREX1-mutated patient.
    Olivieri I; Cattalini M; Tonduti D; La Piana R; Uggetti C; Galli J; Meini A; Tincani A; Moratto D; Fazzi E; Balottin U; Orcesi S
    Lupus; 2013 Sep; 22(10):1064-9. PubMed ID: 23918923
    [TBL] [Abstract][Full Text] [Related]  

  • 14. cGAS phase separation inhibits TREX1-mediated DNA degradation and enhances cytosolic DNA sensing.
    Zhou W; Mohr L; Maciejowski J; Kranzusch PJ
    Mol Cell; 2021 Feb; 81(4):739-755.e7. PubMed ID: 33606975
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intracerebral large artery disease in Aicardi-Goutières syndrome with TREX1 mutation: a case report.
    Wu CC; Peng SS; Lee WT
    Neurol Sci; 2020 Nov; 41(11):3353-3356. PubMed ID: 32524323
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TREX1 deficiency triggers cell-autonomous immunity in a cGAS-dependent manner.
    Ablasser A; Hemmerling I; Schmid-Burgk JL; Behrendt R; Roers A; Hornung V
    J Immunol; 2014 Jun; 192(12):5993-7. PubMed ID: 24813208
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SAMHD1 is a nucleic-acid binding protein that is mislocalized due to aicardi-goutières syndrome-associated mutations.
    Goncalves A; Karayel E; Rice GI; Bennett KL; Crow YJ; Superti-Furga G; Bürckstümmer T
    Hum Mutat; 2012 Jul; 33(7):1116-22. PubMed ID: 22461318
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Measuring TREX1 and TREX2 exonuclease activities.
    Hemphill WO; Perrino FW
    Methods Enzymol; 2019; 625():109-133. PubMed ID: 31455522
    [TBL] [Abstract][Full Text] [Related]  

  • 19. cGAS activation causes lupus-like autoimmune disorders in a TREX1 mutant mouse model.
    Xiao N; Wei J; Xu S; Du H; Huang M; Zhang S; Ye W; Sun L; Chen Q
    J Autoimmun; 2019 Jun; 100():84-94. PubMed ID: 30872080
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genotype-Phenotype Correlation and Functional Insights for Two Monoallelic
    Amico G; Hemphill WO; Severino M; Moratti C; Pascarella R; Bertamino M; Napoli F; Volpi S; Rosamilia F; Signa S; Perrino F; Zedde M; Ceccherini I; On Behalf Of The Gaslini Stroke Study Group
    Genes (Basel); 2022 Jun; 13(7):. PubMed ID: 35885962
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.